Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03189563 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of DA-9805 for Parkinson's Disease

A Phase 2 study of Parkinson's Disease, sponsored by Dong-A ST Co..

Completed
Registry status
Phase 2
Development phase
61
Enrollment target
1
Study location

NCT03189563 is a Phase 2 study of Parkinson's Disease that has completed, run by Dong-A ST Co.. The registered enrollment target is 61 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03189563, a Phase 2 study of Parkinson's Disease, has completed, sponsored by Dong-A ST Co..

COMPLETED
Registry status
Phase 2
Development phase
61 participants
Enrollment target
1
Study location

Study Summary

This is a phase IIa, first in human, randomized, double-blind, multicenter study to evaluate the safety, tolerability and efficacy of DA-9805 at 45mg, 90mg versus placebo in subjects diagnosed with early Parkinson's disease.

Conditions Studied

Parkinson's Disease

Interventions

  • OTHER Placebo
  • DRUG DA-9805 45mg
  • DRUG DA-9805 90mg

Study Locations (1)

Minnesota

  • HealthPartners Institute - Bloomington

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2018-02-06
Est. Completion 2019-04-10
Phase Phase 2

Sponsor

Dong-A ST Co.

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03189563

The ClinicalTrials.gov registry entry for NCT03189563 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (90% lower). The listed sponsor is Dong-A ST Co., which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT03189563 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT03189563 about?

NCT03189563 is a clinical study titled "Safety and Efficacy of DA-9805 for Parkinson's Disease". This is a phase IIa, first in human, randomized, double-blind, multicenter study to evaluate the safety, tolerability and efficacy of DA-9805 at 45mg, 90mg versus placebo in subjects diagnosed with early Parkinson's disease.

What is the current status of trial NCT03189563?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2018-02-06. Estimated completion is 2019-04-10.

What conditions does trial NCT03189563 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT03189563?

The interventions under investigation include: Placebo (OTHER), DA-9805 45mg (DRUG), DA-9805 90mg (DRUG).

Who is sponsoring clinical trial NCT03189563?

This trial is sponsored by Dong-A ST Co., which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03189563 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson's Disease

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.